Sumitomo Mitsui DS Asset Management Company Ltd Has $20.28 Million Position in Boston Scientific Corporation $BSX

Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Boston Scientific Corporation (NYSE:BSX) by 2.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 207,756 shares of the medical equipment provider’s stock after buying an additional 5,445 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Boston Scientific were worth $20,283,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of BSX. FWL Investment Management LLC bought a new stake in Boston Scientific during the second quarter worth about $26,000. Sound Income Strategies LLC increased its holdings in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares during the period. Steph & Co. bought a new stake in shares of Boston Scientific during the 3rd quarter worth approximately $25,000. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific during the 3rd quarter worth approximately $25,000. Finally, Kilter Group LLC bought a new position in Boston Scientific in the second quarter valued at approximately $30,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 93,095 shares of company stock worth $9,305,450 in the last three months. Company insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. BTIG Research reaffirmed a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a report on Friday, November 21st. Leerink Partners upped their price objective on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Evercore ISI set a $112.00 target price on Boston Scientific in a research report on Monday. Cowen reissued a “buy” rating on shares of Boston Scientific in a report on Thursday, December 11th. Finally, UBS Group restated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $125.21.

Boston Scientific Price Performance

BSX stock opened at $97.68 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The firm has a market cap of $144.80 billion, a price-to-earnings ratio of 52.23, a PEG ratio of 1.74 and a beta of 0.67. The company’s fifty day simple moving average is $97.58 and its 200 day simple moving average is $100.78. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company’s quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.